Tonix Pharmaceuticals Holding Corp. completed its initial public offering and transitioned into a publicly traded corporate entity to secure capital for its biopharmaceutical research pipelines. Following its market debut, the company has utilized public equity markets to finance extensive clinical trials, therapeutic discovery platforms, and corporate growth initiatives. Its shares trade under strict regulatory compliance frameworks monitored by U.S. securities authorities, allowing institutional funds and retail investors to participate in open-market transactions.